ALIMERA SCIENCES, INC. (NASDAQ:ALIM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(e) On June 18, 2019, Alimera Sciences, Inc. (the “Company”) held its 2019 annual meeting of stockholders (the “Annual Meeting”) and the Company’s stockholders voted to approve the Alimera Sciences, Inc. 2019 Omnibus Incentive Plan (the “2019 Plan”).

The 2019 Plan replaces the Company’s previous equity compensation plan, the Alimera Sciences, Inc. 2010 Equity Incentive Plan (the “2010 Equity Plan”), effective June 18, 2019, the date of the Annual Meeting, and no new awards will be granted under the 2010 Equity Plan. All awards outstanding under the 2010 Equity Plan, the Company’s 2004 Incentive Stock Plan, as amended, and the Company’s 2005 Incentive Stock Plan, as amended, will continue to be outstanding and governed by the provisions of the applicable plans. Directors, officers, employees and consultants of the Company and its subsidiaries are eligible to receive awards under the 2019 Plan. The number of authorized shares under the 2019 Plan is fixed at 7,500,000, subject to adjustment for certain corporate transactions and for shares forfeited, terminated or surrendered or tendered or for shares withheld to cover withholding taxes for awards other than options or stock appreciation rights, in any such case granted under the 2019 Plan.

The summary of the 2019 Plan is qualified in its entirety by reference to the full text of the 2019 Plan, which is attached as Exhibit 10.60 hereto and is incorporated herein by reference. The form of stock option agreement for use with the 2019 Plan is also attached as Exhibit 10.61.

Item 5.07. Submission of Matters to a Vote of Security Holders.

At the Annual Meeting, the following proposals were submitted to the stockholders of the Company, as set forth in the Company’s definitive proxy statement on Schedule 14A filed with the SEC on April 29, 2019 (the “Proxy Statement”):

On the record date, there were (a) 70,968,630 shares of common stock outstanding and entitled to vote on the basis of one vote per share and (b) shares of our outstanding Series A Preferred Stock entitled to 8,135,593 votes. Of the 79,104,223 votes that were eligible to be cast by the holders of common stock and Series A Preferred Stock at the Annual Meeting, 56,374,842 votes, or approximately 71.3% of the total, were represented at the meeting in person or by proxy, constituting a quorum. The number of votes cast for, against or withheld, as well as abstentions and broker non-votes, if applicable, in respect of each such matter is set forth below:

The Company’s stockholders elected the following directors to serve as Class III directors until the 2022 annual meeting of stockholders. The votes regarding the election of these directors were as follows:

The Company’s stockholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019. The votes regarding this proposal were as follows: